128 related articles for article (PubMed ID: 63802)
1. Evidence that endogenous calcitonin protects against renal bone disease.
Kanis JA; Oliver D; Ledingham JC; Russell RG
Lancet; 1976 Dec; 2(7999):1322-6. PubMed ID: 63802
[TBL] [Abstract][Full Text] [Related]
2. Responses to salmon calcitonin in chronic renal failure: relation to histological and biochemical indices of bone turnover.
Cundy T; Heynen G; Gaspar S; Earnshaw M; Bartlett M; Paton S; Kanis JA
Eur J Clin Invest; 1981 Jun; 11(3):177-84. PubMed ID: 6791936
[TBL] [Abstract][Full Text] [Related]
3. Changes in histologic and biochemical indexes of bone turnover after bilateral nephrectomy in patients on hemodialysis. Evidence for a possible role of endogenous calcitonin.
Kanis JA; Earnshaw M; Heynen G; Ledingham JG; Oliver DO; Russell GG; Woods CG; Franchimont P; Gaspar S
N Engl J Med; 1977 May; 296(19):1073-9. PubMed ID: 850517
[TBL] [Abstract][Full Text] [Related]
4. [Variations in serum levels of phosphorus (iP), calcium (Ca), calcitonin (iCT) and parathormone (iPTH) in patients under periodic hemodialysis. Effects of exogenous calcitonin therapy].
Bucciante G; Bernardi A; Biasia F; Milan G; Donato D
Minerva Med; 1985 Mar; 76(9-10):415-7. PubMed ID: 3982698
[No Abstract] [Full Text] [Related]
5. [Effect of salmon calcitonin on bone mineral density and calcium-phosphate metabolism in chronic hemodialysis patients with secondary hyperparathyroidism].
Matuszkiewicz-Rowińska J; Niemczyk S; Przedlacki J; Puka J; Switalski M; Ostrowski K
Pol Arch Med Wewn; 2004 Jul; 112(1):797-803. PubMed ID: 15526839
[TBL] [Abstract][Full Text] [Related]
6. The possible role of calcitonin deficiency in the development of bone disease due to chronic renal failure.
Kanis JA; Earnshaw M; Heynen G; Russell RG; Woods CG
Calcif Tissue Res; 1977 May; 22 Suppl():147-53. PubMed ID: 912516
[No Abstract] [Full Text] [Related]
7. Evidence for a relationship between plasma immunoreactive calcitonin and bone disease in chronic renal failure.
Kanis JA; Heynen G; Earnshaw M; Russell RG; Woods CG; Franchimont P; Gaspar S; Oliver D; Ledingham JG
Adv Exp Med Biol; 1977; 81():571-9. PubMed ID: 899941
[No Abstract] [Full Text] [Related]
8. Is bone loss in chronic renal failure sex-dependent.
Christiansen C; Hartnack B; Transbøl I
Lancet; 1977 Jun; 1(8026):1370. PubMed ID: 69092
[No Abstract] [Full Text] [Related]
9. Influence of calcium infusion on calcitonin and parathyroid hormone concentrations in normal and hemodialyzed subjects.
Isaac R; Nivez MP; Piamba G; Fillastre JP; Ardaillou R
Clin Nephrol; 1975 Jan; 3(1):14-7. PubMed ID: 1126058
[TBL] [Abstract][Full Text] [Related]
10. Immunoreactive parathyroid hormone and calcitonin in plasma and ultrafiltrate before and after haemodialysis.
Fauchald P; Gautvik VT; Gautvik KM
Scand J Clin Lab Invest; 1985 May; 45(3):229-35. PubMed ID: 4001828
[TBL] [Abstract][Full Text] [Related]
11. Normal calcitonin response to pentagastrin stimulation in patients with chronic renal failure.
Escalada J; Teruel JL; Pavón I; Vila T; Navarro J; Varela C
Acta Endocrinol (Copenh); 1993 Jul; 129(1):39-41. PubMed ID: 8351957
[TBL] [Abstract][Full Text] [Related]
12. Total body calcium and long-term calcium balance in chronic renal disease.
Denney JD; Sherrard DJ; Nelp WB; Chesnut CH; Baylink DJ
J Lab Clin Med; 1973 Aug; 82(2):226-40. PubMed ID: 4721378
[No Abstract] [Full Text] [Related]
13. Parathyroid gland sonography in relation to markers of bone metabolism in kidney transplant recipients.
Małyszko J; Łebkowska U; Wołczyński S; Małyszko JS; Myśliwiec M
Transplant Proc; 2002 Mar; 34(2):593-5. PubMed ID: 12009635
[No Abstract] [Full Text] [Related]
14. Effect of calcitonin on hemodialysis patients with hypercalcemia and renal osteodystrophy.
Carney SL; Epstein MT
Uremia Invest; 1984-1985; 8(2):97-101. PubMed ID: 6537690
[TBL] [Abstract][Full Text] [Related]
15. Biological activity of endogenous and exogenous calcitonin in patients with osteitis fibrosa and chronic renal failure.
Cundy T; Heynen G; Paton S; Ledingham JG; Russell RG; Oliver DO; Kanis JA
Proc Eur Dial Transplant Assoc; 1978; 15():524-31. PubMed ID: 740683
[TBL] [Abstract][Full Text] [Related]
16. Effect of phosphate binging agents on bone remodelling in patients on regular haemodialysis.
Fournier A; Tunchot S; Bedrossian J; Sionest JG; Idatte JM; Bordier P
Proc Eur Dial Transplant Assoc; 1972; 9():126-41. PubMed ID: 4668905
[No Abstract] [Full Text] [Related]
17. Serum parathyroid hormone concentration in chronic renal failure patients on maintenance haemodialysis.
Wills MR; Fairney A; Varghese Z; Tatler GL; Baillod RA; Moorhead JF
Clin Chim Acta; 1974 Nov; 57(1):83-9. PubMed ID: 4430145
[No Abstract] [Full Text] [Related]
18. [Effect of hemofiltration on plasma levels of parathyroid hormone and calcitonin].
De Fremont JF; Fournier A; Gueris J; Caillens C; Coevoet B; Lambrey G; Quichaud J
J Urol Nephrol (Paris); 1978; 84(4-5):323-8. PubMed ID: 682233
[No Abstract] [Full Text] [Related]
19. Can low-dosage aluminium hydroxide control the plasma phosphate without bone toxicity?
Jenkins DA; Gouldesbrough D; Smith GD; Cowie JF; Winney RJ
Nephrol Dial Transplant; 1989; 4(1):51-6. PubMed ID: 2494599
[TBL] [Abstract][Full Text] [Related]
20. [Correlations between osteodensitometry and parameters of uremic osteodystrophy].
Sforzini S; Viganò MR; Beretta P; Rosa M; d'Amico P; Lomuscio G; Paesani R
Minerva Med; 1985 Mar; 76(9-10):445-8. PubMed ID: 3982703
[No Abstract] [Full Text] [Related]
[Next] [New Search]
